X4 Pharms Drug Patent Portfolio
X4 Pharms owns 1 orange book drug protected by 6 US patents Given below is the list of X4 Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10548889 | Compositions of CXCR4 inhibitors and methods of preparation and use | 11 Dec, 2038 | Active |
| US11045461 | Compositions of CXCR4 inhibitors and methods of preparation and use | 11 Dec, 2038 | Active |
| US12115156 | Compositions of CXCR4 inhibitors and methods of preparation and use | 11 Dec, 2038 | Active |
| US10610527 | Methods for treating immunodeficiency disease | 22 Dec, 2036 | Active |
| US11219621 | Methods for treating immunodeficiency disease | 22 Dec, 2036 | Active |
| US10953003 | Methods for treating cancer | 14 Dec, 2036 | Active |
X4 Pharms's Family Patents
X4 Pharms Drug List
Given below is the complete list of X4 Pharms's drugs and the patents protecting them.
1. Xolremdi
Xolremdi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10548889 | Compositions of CXCR4 inhibitors and methods of preparation and use |
11 Dec, 2038
(14 years from now)
| Active |
| US11045461 | Compositions of CXCR4 inhibitors and methods of preparation and use |
11 Dec, 2038
(14 years from now)
| Active |
| US12115156 | Compositions of CXCR4 inhibitors and methods of preparation and use |
11 Dec, 2038
(14 years from now)
| Active |
| US10610527 | Methods for treating immunodeficiency disease |
22 Dec, 2036
(12 years from now)
| Active |
| US11219621 | Methods for treating immunodeficiency disease |
22 Dec, 2036
(12 years from now)
| Active |
| US10953003 | Methods for treating cancer |
14 Dec, 2036
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xolremdi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List